UK's NICE publishes updated draft guidance on RA medications, does not recommend Celgene's Otezla

19 June 2015

The UK’s National Institute for Health and Care Excellence (NICE) has released new draft updated guidance, recommending several drugs in combination with methotrexate as options for treating severe rheumatoid arthritis where disease has not responded to intensive therapy with a combination of conventional disease-modifying antirheumatics.

The draft updated guidance has been published today for consultation on the following drugs: Humira (adalimumab) from AbbVie (NYSE: ABBV), Enbrel (etanercept) from Pfizer (NYSE: PFE), Remicade (infliximab) and Simponi (golimumab) from Merck (NYSE: MRK), Cimzia (certolizumab) from UCB (Euronext Brussels: UCB), RoActemra (tocilizumab) from Roche (SIX: ROG) and Orencia (abatacept) from Bristol-Myers Squibb (NYSE: BMY), which have been recommended.

The NICE also published new draft guidance which does not recommend Otezla (apremilast) from Celgene (Nasdaq: CELG) for adults with active psoriatic arthritis that has either not responded to disease-modifying antirheumatic drug therapy, or where such therapy is not tolerated.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK